• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MBX Biosciences Inc.

    11/8/24 10:52:39 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    MBX Biosciences, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    55287L101


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 55287L101

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 2,789,254
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 2,937,853
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,937,853
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.22%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 55287L101

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 2,789,254
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 2,937,853
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,937,853
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.22%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 55287L101

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 2,789,254
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 2,937,853
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,937,853
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.22%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 55287L101

    1. NAMES OF REPORTING PERSONS

    Wellington Management Company LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 2,789,254
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 2,922,425
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,922,425
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.17%
    12. TYPE OF REPORTING PERSON

    IA

    Item 1.
    (a) Name of Issuer
    MBX Biosciences, Inc.
    (b) Address of Issuer's Principal Executive Offices
    11711 North Meridian Street
    Suite 300
    Carmel, IN 46032
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    Wellington Management Company LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    Wellington Management Company LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    55287L101
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Wellington Management Group LLP - HC
    Wellington Group Holdings LLP - HC
    Wellington Investment Advisors Holdings LLP - HC
    Wellington Management Company LLP - IA
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:


    Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
    Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Management Company LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    Get the next $MBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    10/8/2024$44.00Buy
    Guggenheim
    10/8/2024$40.00Buy
    Stifel
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$30.00Overweight
    JP Morgan
    More analyst ratings

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mathers Edward T

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      6/6/25 11:29:01 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoerter Steven L.

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      6/6/25 8:59:30 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aynechi Tiba

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      6/6/25 8:05:48 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    SEC Filings

    See more
    • MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      6/16/25 8:02:57 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      6/9/25 7:59:27 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      6/6/25 7:59:29 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

      CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. "Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of lea

      6/23/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

      GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX's novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MBX 4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GI

      6/16/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

      CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced presentations at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20-23. 2025, Chicago, IL. 846-P - Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers: A Phase 1 Randomized TrialPresenter: Elisa Fabbrini, MD. PhD. Session: General Poster SessionDate: Sunday June 22nd, 2025 Time 12:30-1:30pm CT845-P - M

      6/10/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on MBX Biosciences with a new price target

      Citizens JMP initiated coverage of MBX Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

      4/10/25 12:42:19 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on MBX Biosciences with a new price target

      Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on MBX Biosciences with a new price target

      Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pescovitz Ora H. bought $45,312 worth of shares (7,693 units at $5.89), increasing direct ownership by 46% to 24,329 units (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/10/25 8:39:55 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gordon Carl L bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:56:33 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:52:03 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/8/24 10:52:39 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/1/24 5:38:56 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MBX Biosciences Inc.

      SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

      9/23/24 6:07:21 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    See more
    • MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

      CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. "Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of lea

      6/23/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

      5/12/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

      CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

      4/7/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Financials

    Live finance-specific insights

    See more
    • MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

      Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

      1/7/25 7:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care